Advanced Solid Tumors Clinical Trials in Nashville, Tennessee

23 studies are recruiting for advanced solid tumors in Nashville, Tennessee right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

   This is a first-in-human, Phase I, open-label, multicenter, dose-escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of VVD-133214 monotherapy, and in combination with bevacizumab or pembrolizumab, in part…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   SCRI Oncology Partners, Nashville, Tennessee

   Locations

   47 in total

   Run by

   Vividion Therapeutics, Inc.

   See if you can join NCT06004245 on ClinicalTrials.gov

2. First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

   The goal of this study is to identify a safe and tolerated dose of the orally administered KIF18A inhibitor ATX-295. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and preliminary antitumor activity of ATX-295 in patients with advanced solid tumors and ovarian cancer.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   SCRI Oncology Partners, Nashville, Tennessee

   Locations

   9 in total

   Run by

   Accent Therapeutics

   See if you can join NCT06799065 on ClinicalTrials.gov

3. A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

   Researchers are looking for a better way to treat people who have solid tumors with HER2-activating mutations. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety and how it works. In this trial, the researchers want to learn how wel…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   SCRI Oncology Partners, Nashville, Tennessee

   Locations

   54 in total

   Run by

   Bayer

   See if you can join NCT06760819 on ClinicalTrials.gov

4. TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

   The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to character limits, the arms section does NOT include …

   Stage

   Phase 2

   Ages

   12 and older

   Site

   Tennessee Oncology - Nashville / Sarah Cannon Research Institute, Nashville, Tennessee

   Locations

   181 in total

   Run by

   American Society of Clinical Oncology

   See if you can join NCT02693535 on ClinicalTrials.gov

5. A Study of JNJ-87890387 for Advanced Solid Tumors

   The purpose of this study is to determine safety and recommended phase 2 dose(s) (RP2Ds) of JNJ-87890387 and to determine the safety of JNJ-87890387 at the RP2D(s).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sarah Cannon Research Institute, Nashville, Tennessee

   Locations

   6 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT06178614 on ClinicalTrials.gov

6. A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors

   This is an open-label, multicenter phase 1 study to evaluate the safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0505 in Adult Participants with Advanced Solid Tumors

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sarah Cannon Research Institute (SCRI) - Nashville, Nashville, Tennessee

   Locations

   17 in total

   Run by

   NextCure, Inc.

   See if you can join NCT06792552 on ClinicalTrials.gov

7. A Study of PHST001 in Advanced Solid Tumors

   This is a multi-center, first-in-human (FIH), open-label, Phase 1a/1b dose escalation and dose expansion study to assess the safety, PK, pharmacodynamics, and antitumor activity of PHST001 monotherapy (Phase 1a) or in combination with chemotherapy (Phase 1b) in adult participants with advanced rela…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sarah Cannon Research Institute (SCRI) Oncology Partners, Nashville, Tennessee

   Locations

   20 in total

   Run by

   Pheast Therapeutics

   See if you can join NCT06840886 on ClinicalTrials.gov

8. A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.

   This study aims to evaluate the effects of rezatapopt on the pharmacokinetics of metformin, rosuvastatin, repaglinide, and midazolam in patients with advanced solid tumors harboring a TP53 Y220C mutation.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   SCRI Oncology Partners, Nashville, Tennessee

   Locations

   5 in total

   Run by

   PMV Pharmaceuticals, Inc

   See if you can join NCT07372625 on ClinicalTrials.gov

9. A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

   This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent and in combination with chemotherapy administered intravenously in participants with advanced solid tumors that are antigen-rich.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Sarah Cannon Research Institute Oncology Partners (SCRI-Nashville), Nashville, Tennessee

   Locations

   19 in total

   Run by

   Marengo Therapeutics, Inc.

   See if you can join NCT05592626 on ClinicalTrials.gov

10. A Study of PHN-012 in Patients With Advanced Solid Tumors

    This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of PHN-012, a novel antibody-drug conjugate (ADC), in patients with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    PHN-012-001 Site, Nashville, Tennessee

    Locations

    26 in total

    Run by

    Pheon Therapeutics

    See if you can join NCT07127874 on ClinicalTrials.gov

11. Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

    The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RAS(ON) inhibitors in combination with ivonescimab in adults with advanced or metastatic solid tumors with a RAS mutation.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Tennessee Oncology, Nashville, Tennessee

    Locations

    9 in total

    Run by

    Revolution Medicines, Inc.

    See if you can join NCT07397338 on ClinicalTrials.gov

12. Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

    A Phase 1 study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary antitumor activity of TYRA-430 in cancers with FGF/FGFR pathway aberrations, including locally advanced/metastatic hepatocellular carcinoma and other advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Sarah Cannon Research Institute Oncology Partners, Nashville, Tennessee

    Locations

    16 in total

    Run by

    Tyra Biosciences, Inc

    See if you can join NCT06915753 on ClinicalTrials.gov

13. A Study of ASP1002 in Adults for Treatment of Solid Tumors

    ASP1002 is being studied in people with tumors that have spread to nearby tissue (locally advanced) that cannot be removed by surgery (unresectable) or tumors that have spread to other parts of the body (metastatic). Claudin 4 protein, or CLDN4, is a protein found on tumors in different parts of th…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    SCRI Oncology Partners, Nashville, Tennessee

    Locations

    15 in total

    Run by

    Astellas Pharma Global Development, Inc.

    See if you can join NCT05719558 on ClinicalTrials.gov

14. Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

    The primary goal of this study is to assess the safety and tolerability of mRNA-4359 administered alone and in combination with pembrolizumab or ipilimumab and nivolumab.

    Stage

    Phase 1

    Ages

    12 and older

    Site

    Sara Cannon Research Institute Tennessee, Nashville, Tennessee

    Locations

    39 in total

    Run by

    ModernaTX, Inc.

    See if you can join NCT05533697 on ClinicalTrials.gov

15. A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

    The purpose of this study is to characterize the safety and tolerability of ALTA3263 in adults with advanced solid tumors with KRAS mutations.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Research Site, Nashville, Tennessee

    Locations

    12 in total

    Run by

    Alterome Therapeutics, Inc.

    See if you can join NCT06835569 on ClinicalTrials.gov

16. An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

    The primary objectives of this trial are to: * Characterize the safety and tolerability of TEV-56278 * Determine the Recommended Phase 2 Dose (RP2D) * Evaluate antitumor activity of TEV-56278 (Part 2 only) * Determine the safety and tolerability of TEV-56278 in combination with pembrolizumab * Dete…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Teva Investigational Site 12019, Nashville, Tennessee

    Locations

    12 in total

    Run by

    Teva Branded Pharmaceutical Products R&D LLC

    See if you can join NCT06480552 on ClinicalTrials.gov

17. Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

    This study is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Sarah Cannon Research Institute, Nashville, Tennessee

    Locations

    17 in total

    Run by

    Revolution Medicines, Inc.

    See if you can join NCT06040541 on ClinicalTrials.gov

18. A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors

    This is a first-in-human (FIH), open-label, multicenter dose escalation and expansion study of ALK201. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of ALK201 as a monotherapy in adult participants with Advanced Solid Tumors. The st…

    Stage

    Phase 1

    Ages

    18 to 75

    Site

    Sarah Cannon Research Institute Oncology Partners, Nashville, Tennessee

    Locations

    38 in total

    Run by

    Shanghai Allink Biotherapeutics Co., Ltd.

    See if you can join NCT06656390 on ClinicalTrials.gov

19. Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

    Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Sarah Cannon Research Institute, Nashville, Tennessee

    Locations

    21 in total

    Run by

    Revolution Medicines, Inc.

    See if you can join NCT05379985 on ClinicalTrials.gov

20. A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors

    A FIH dose escalation and dose expansion study to evaluate VVD-130037 in participants with advanced solid tumors as a single agent, and in combination with docetaxel, paclitaxel, or pembrolizumab.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Sarah Cannon Research Institute, Nashville, Tennessee

    Locations

    26 in total

    Run by

    Vividion Therapeutics, Inc.

    See if you can join NCT05954312 on ClinicalTrials.gov

21. SNV4818 in Participants With Advanced Solid Tumors

    This study is testing a new medicine, SNV4818, for people with advanced cancers. The researchers want to find out if SNV4818 is safe, well-tolerated, and effective in treating solid tumors. They are investigating different doses in order to find the safest and most effective one.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Sarah Cannon Research Institute, Nashville, Tennessee

    Locations

    12 in total

    Run by

    Pikavation Therapeutics, Inc.

    See if you can join NCT06736704 on ClinicalTrials.gov

22. A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

    This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Research Site 136, Nashville, Tennessee

    Locations

    107 in total

    Run by

    DualityBio Inc.

    See if you can join NCT05914116 on ClinicalTrials.gov

23. A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

    This is a first-in-human, Phase 1/2 study to evaluate LCB84, a TROP2-directed antibody-drug conjugate, alone and in combination with an anti-PD-1 Ab, in dose escalation (Phase 1) followed by dose expansion (Phase 2). The study population in dose escalation (Phase 1) consists of patients with advanc…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Tennessee Oncology, Nashville, Tennessee

    Locations

    8 in total

    Run by

    LigaChem Biosciences, Inc.

    See if you can join NCT05941507 on ClinicalTrials.gov